Skip to main content
. 2021 Apr 15;11(4):1012–1030.

Figure 6.

Figure 6

De-differentiation and clonal evolution of prostate cancer cells. The castrate resistant prostate cancer (CRPC) cells are resistant to hormonal therapy. Constitutive androgen deprivation and androgen receptor ablation therapies may lead to absolute non-response and de-differentiation of the already CRPC to SCPC and clonal evolution of this cell population.